FB 401
Alternative Names: FB-401Latest Information Update: 26 Dec 2022
At a glance
- Originator National Institute of Allergy and Infectious Diseases
- Class Anti-inflammatories; Bacteria; Skin disorder therapies
- Mechanism of Action Bacteria replacements; Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Atopic dermatitis
Most Recent Events
- 30 Sep 2021 Discontinued - Phase-II for Atopic dermatitis (In adolescents, In children, In adults) in USA (Topical)
- 30 Sep 2021 Forte Biosciences terminates a phase II trial for Atopic dermatitis (In adolescents, In children, In adults) in USA (Topical), due to failure of phase II FB401-01 trial (NCT04936113)
- 02 Sep 2021 Efficacy data from a phase II trial in Atopic dermatitis released by Forte Biosciences